Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiorenal effects of therapies for type 2 diabetes and obesity.

The British journal of cardiology·2026
Same author

Metformin: Antidiabetic actions from cells to tissues.

Metabolism: clinical and experimental·2026
Same author

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Peptides·2026
Same author

Pharmacological therapies for type 2 diabetes: future approaches.

Diabetologia·2025
Same author

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Peptides·2025
Same author

Diabetes and gout: another role for SGLT2 inhibitors?

Therapeutic advances in endocrinology and metabolism·2024

Related Experiment Video

Updated: May 11, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Interpreting adverse signals in diabetes drug development programs.

Clifford J Bailey1

  • 1School of Life and Health Sciences, Aston University, Birmingham, UK. c.j.bailey@aston.ac.uk

Diabetes Care
|May 23, 2013
PubMed
Summary

Interpreting adverse signals in drug development is challenging, especially for diabetes therapies. Ongoing monitoring and real-world data refine understanding of drug benefits and risks over time.

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Clinical Pharmacology
  • Endocrinology and Metabolism

Background:

  • Adverse signal detection and interpretation are crucial for drug benefit-risk assessment.
  • Clinical trials have limitations in predicting long-term real-world outcomes.
  • Diabetes therapies face unique challenges due to comorbidities and interactions.

Purpose of the Study:

  • To review recent adverse signals associated with diabetes therapies.
  • To illustrate challenges in causality assessment, risk evaluation, and predictability.
  • To emphasize the need for ongoing benefit-risk refinement.

Main Methods:

  • Review of recent adverse signals in diabetes therapies.
  • Analysis of limitations in clinical trial design (patient selection, duration, bias).

More Related Videos

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature

Published on: December 26, 2017

Related Experiment Videos

Last Updated: May 11, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature

Published on: December 26, 2017

  • Discussion of confounding factors in diabetes risk assessment (comorbidities, drug interactions).

    • Main Results:

    • Difficulty in attributing causality and evaluating absolute risk for diabetes drug signals.
    • Clinical trials may not fully predict long-term adverse effects emerging years later.
    • Confounding factors in diabetes complicate risk assessment and therapeutic choices.

    Conclusions:

    • Benefit-risk assessments for diabetes therapies require continuous refinement with accumulating data.
    • Early signals in trials may not capture all potential long-term adverse events.
    • Adjustments to prescribing indications are necessary as experience with therapies grows.